SG
DNTH icon

StoneX Group’s Dianthus Therapeutics DNTH Stock Holding History

StoneX Group’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-765
Closed -$4.83K – 735
2022
Q4 		$4.83K Buy
+765
New +$13.5K ﹤0.01% 602

Other funds holding DNTH

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WSL
Western Standard LLC Los Angeles, California $295M AUM 40.98% 1-Year Est. Return
TG
TCW Group Los Angeles, California $14.9B AUM 46.29% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

StoneX Group's DNTH Position: Q1 2023 in Review

StoneX Group sold out of Dianthus Therapeutics (DNTH) in Q1 2023, closing a stake of 765 shares — an estimated $4.83K sold.

StoneX Group first reported a position in DNTH in Q4 2022 and held it in 1 quarter. The position peaked at $4.83K in Q4 2022. 52 funds tracked by Wall St. Rank hold DNTH as of Q1 2023.

  • StoneX Group reported no remaining Dianthus Therapeutics position as of Q1 2023 after selling out during the quarter.
  • StoneX Group sold 765 Dianthus Therapeutics shares in Q1 2023, an estimated $4.83K.
  • StoneX Group first reported a position in Dianthus Therapeutics in Q4 2022 and held it in 1 quarter.
  • StoneX Group's Dianthus Therapeutics position peaked at $4.83K in Q4 2022.
  • 52 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2023.

Based on StoneX Group's 13F filing for Q1 2023, filed 11 May 2023.